On Nov. 2, 2020, Nostrum Laboratories, Inc., announced that it has recalled two lots of its Type 2 diabetes drug Metformin due to it containing high levels of NDMA, a possible human carcinogen. The affected lots include Metformin HCI Extended Release Tablets, USP 750 mg, with lot numbers MET200101 and MET200301. Both lots have an expiration date of 5/2022.
Many medications have been recalled in recent months due to contamination with NDMA, including blood pressure medications and acid reflux medications. NDMA is a naturally occurring substance, but it should only be present in food, beverages, and medications in very small amounts.
The affected lots of Metformin were found to have higher than allowed levels of the contaminant, which could put patients’ health at risk. In the U.S. Food and Drug Administration’s release concerning the recall, the agency indicates that Nostrum Laboratories is notifying distributors of the affected lots by letter and is arranging for return of all recalled products.
If you or someone you love has a lot of Metformin that’s included in this recall, you should talk to your doctor or pharmacist about getting a replacement batch. Never stop taking this or any other medication without speaking to your doctor first.
At Ferrer Poirot Feller Daniel, we are always on the lookout for potentially dangerous medications. Unfortunately, new medications are recalled frequently, and that means innocent patients are putting their health at risk unknowingly. It’s our goal to hold negligent drug manufacturers accountable when their lax safety standards allow dangerous drugs to enter the market.